Cell 172 , 176190 e119 (2018)
Putting the evidence side by side Here is the blunt comparison: AOD 9604: 2.6 kg weight loss in 12 weeks (best result), failed six clinical trials, development terminated Semaglutide: 15 to 17 percent body weight loss over 68 weeks, FDA approved, thousands of study participants, consistent results across multiple trials There is no way to frame this comparison that puts AOD 9604 on equal footing with semaglutide when it comes to clinical evidence
Still, the GHK-Cu peptide is not an anti-aging miracle or one-size-fits-all solution
Cellular-Response Research Research involving GHK-Cu has explored its interaction with: Cellular-repair and regenerative signaling pathways Oxidative-stress and antioxidant-defense mechanisms Tissue-remodeling and extracellular-matrix pathways Cellular-response and physiological-maintenance signaling Because GHK-Cu interacts with regenerative and growth-related pathways, some research settings involving active cancer-, tumor-, or abnormal proliferative research models may warrant additional monitoring and individualized evaluation
Isopropyl -d-1-thiogalactopyranoside (IPTG) was added to a final concentration of 1 mM and the culture was further incubated at 18 C overnight
